Nejm Dostarlimab Endometrial Cancer, 4% with dostarlimab and On Augu
Nejm Dostarlimab Endometrial Cancer, 4% with dostarlimab and On August 1, 2024, the Food and Drug Administration approved dostarlimab-gxly (Jemperli, GSK) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for adult patients with Adding immunotherapy to chemotherapy substantially increases how long people with advanced endometrial cancer live without their cancer worsening, two studies show. 64) with a favorable OS trend (HR, 0. [5][6][10] Dostarlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody. FDA has approved three new immunotherapy options, including pembrolizumab (Keytruda) and durvalumab (Imfinzi), with chemo for advanced endometrial cancer. This review summarizes the rationale, evidence, and indications for the use of dostarlimab in advanced and recurrent endometrial cancer. This helps prevent cancer cells from evading the immune system's Mismatch repair-deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. We conducted a phase 3, global, double-blind, randomized, placebo-controlled trial. Although the agent is substantially more costly, dostarlimab became cost-effective when its cost was reduced to $5489 per cycle. Dostarlimab in combination with carboplatin-paclitaxel demonstrated a statistically significant and clinically meaningful OS benefit in the overall population of patients with primary advanced or recurrent EC while demonstrating an acceptable safety profile. The efficacy of PD-1 FDA has approved three new immunotherapy options, including pembrolizumab (Keytruda) and durvalumab (Imfinzi), with chemo for advanced endometrial cancer. Abstract Purpose: This interim report of the GARNET phase I trial presents efficacy and safety of dostarlimab in patients with advanced or recurrent endometrial cancer (EC), with an analysis of tumor biomarkers as prognostic indicators. Tewari, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer. hospitals with high adherence to quality measures for the t Thymectomy has been a mainstay in the treatment of myasthenia gravis, but there is no conclusive evidence of its benefit. Dostarlimab is an immune checkpoint inhibitor with a favourable safety profile and proven efficacy in the treatment of endometrial cancer, particularly dMMR endometrial cancer. We report interim data from patients with endometrial cancer (EC) participating in a phase I trial of single-agent dostarlimab. On August 1, 2024, the Food and Drug Administration approved dostarlimab-gxly (Jemperli, GSK) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for adult patients with On August 1 st, 2024, the United States Food and Drug Administration expanded the indication of the immunologic anti-PD-1 checkpoint inhibitor, dostarlimab, and chemotherapy in endometrial cancer. May 14, 2025 · “These longer-term (> 3-year) follow-up data further support frontline use of dostarlimab plus carboplatin and paclitaxel as standard of care in all patients with primary advanced or recurrent endometrial cancer,” the authors concluded in the poster. We conducted a multicenter, randomized trial comparing thymectomy plus pred Long-term outcomes are poor with standard first-line chemotherapy for primary advanced or recurrent endometrial cancer. Graphical method was used for hypothesis testing of PFS in the dMMR/MSI-H population, then the overall population, and OS in the overall popula Pembrolizumab plus chemotherapy provides clinically meaningful benefit as first-line therapy for advanced (locoregional extension and residual disease after surgery)/metastatic/recurrent mismatch repair-proficient (pMMR) and mismatch repair-deficient (dMMR) endometrial cancer, with greater magnitude of benefit in the dMMR phenotype. 1 and OS. Although a randomized study has not yet been conducted, dostarlimab monotherapy should be the treatment of choice for patients with advanced MMRd EC in progression after a platinum-containing regimen. Thus, our goal was to assess the efficacy of Dostarlimab, a PD-1 inhibitor, in EC by incorporating data from clinical trials to create a Dostarlimab is associated with greater survival compared with other treatments for women with recurrent dMMR endometrial cancer. Trials have shown that adding dostarlimab (Jemperli) to chemotherapy can slow the spread of certain A randomized trial compared standard chemotherapy plus dostarlimab or placebo. Chase; Brian M. Slomovitz; René dePont Christensen; Zoltán Novàk; et al 出版日期：2023-03-27 求助人 Nike 在 2026-02-13 23:23:21 发布自 江苏，悬赏 20 积分 下载 已经有人上传了文献，正在等待求助者确认 Eligible patients with primary advanced stage III or IV or first recurrent endometrial cancer were randomly assigned in a 1:1 ratio to receive either dostarlimab (500 mg) or placebo, plus Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer Overview Accreditation Register/Take course The AZUR-1 trial aims to confirm the findings of the supported collaborative study in locally advanced dMMR rectal cancer led by Dr. Cercek at MSK. Evidence-based recommendations on dostarlimab (Jemperli) with platinum-based chemotherapy for primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults The AZUR-1 trial aims to confirm the findings of the supported collaborative study in locally advanced dMMR rectal cancer led by Dr. It works by blocking a protein called PD-1 on T cells, which allows these cells to better recognize and attack cancer cells. New Long-term outcomes are poor with standard first-line chemotherapy for primary advanced or recurrent endometrial cancer. Mar 27, 2023 · Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. The combination of chemotherapy and immunotherapy may have synergistic effects in the treatment of Mar 27, 2023 · In this double-blind, placebo-controlled, randomized, phase 3 trial, we assigned 816 patients with measurable disease (stage III or IVA) or stage IVB or recurrent endometrial cancer in a 1:1 Mar 27, 2023 · Dostarlimab plus carboplatin-paclitaxel significantly increased progression-free survival among patients with primary advanced or recurrent endometrial cancer, with a substantial benefit in the dMMR-MSI-H population. S. Jun 9, 2024 · Part 1 of the RUBY trial (NCT03981796) evaluated dostarlimab plus carboplatin–paclitaxel compared with placebo plus carboplatin–paclitaxel in patients with primary advanced or recurrent endometrial cancer (EC). Dostarlimab plus chemotherapy demonstrated a meaningful overall survival improvement in primary endometrial cancer, regardless of mismatch repair status. In this study we aimed to compare the survival outcomes of patients with recurrent or advanced endometrial cancer. [5][6][8] A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer (RUBY) These findings were simultaneously published in the New England Journal of Medicine (2023; doi: 10. Obesity is a global health challenge with few pharmacologic options. Immune checkpoint inhibitors have emerged as novel treatment options in patients with endometrial cancer. The NHS will roll out a new immunotherapy that could offer women with advanced endometrial cancer significant extra time before their disease progresses, compared with standard chemotherapy alone. For patients with primary advanced or recurrent endometrial cancer, dostarlimab plus carboplatin-paclitaxel increases progression-free survival versus carboplatin-paclitaxel alone, according to a Noting the significant impact dostarlimab had on survival benefit without significant added toxicity, which investigators reported as early as March 2023, Salani said it was “wonderful” to have a relatively short turnaround time in making the combination therapy available for patients with primary advanced or recurrent endometrial cancer. Whether adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2. Stage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence. Mechanism of action of Dostarlimab: Dostarlimab, also known as TSR-042 or Jemperli, is an immunotherapy drug that helps the immune system fight cancer. Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Objectives Immune checkpoint inhibitors have emerged as novel treatment options in patients with endometrial cancer. In this randomized phase 3 trial, we tested whether 6 months of platinum-based chemotherapy p This second interim analysis builds on prior results of the trial published in The New England Journal of Medicine, 2 which led to the US Food and Drug Administration’s approval of dostarlimab combined with carboplatin and paclitaxel followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer with Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer. Patients with mismatch repair–deficient tumors had 2-year progression-free survival of 61. Despite FDA approval and peer-reviewed publication in the New England Journal of Medicine, most insurance companies are denying coverage, classifying dostarlimab as "experimental immunotherapy" despite clinical evidence of complete cure. Sep 8, 2025 · Dostarlimab, a PD-1–blocking antibody, has shown promising results in treating advanced or recurrent endometrial cancer, particularly in patients with mismatch repair–deficient (dMMR) tumors. Krishnansu S. These patients had received dostarlimab after platinum-based chemotherapy in the single-arm, Phase I GARNET trial. In the phase 3 RUBY trial (NCT03981796) dostarlimab (D) + carboplatin-paclitaxel (CP) significantly improved PFS vs CP alone in the mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H; HR, 0. We evaluated the addition of pembrolizumab to adjuvant RUBY Part 2 Results In an update on Part 2 of the RUBY trial, the addition of niraparib to dostarlimab in the maintenance setting significantly improved progression-free survival in first-line primary advanced or recurrent endometrial cancer compared to chemotherapy alone, meeting the primary endpoint of the trial. Whether adding immunotherapy could improve outcomes is uncertain. . This phase 3 trial evaluated its effectiveness as a single agent in this population. AZUR-2 is a phase III trial evaluating the efficacy of perioperative dostarlimab compared with SoC in participants with untreated T4N0 or Stage III (resectable) dMMR/MSI-H colon cancer. Noting the significant impact dostarlimab had on survival benefit without significant added toxicity, which investigators reported as early as March 2023, Salani said it was “wonderful” to have a relatively short turnaround time in making the combination therapy available for patients with primary advanced or recurrent endometrial cancer. 1056/NEJMoa2216334). 64). 28) and overall population (HR, 0. The RUBY trial is a phase III, global, randomized, double-blind, multicenter, placebo-controlled study evaluating the efficacy and safety of dostarlimab combined with standard chemotherapy (carboplatin and paclitaxel) in patients with advanced or recurrent endometrial cancer. “Carboplatin/paclitaxel is standard of care for first-line treatment of primary advanced or recurrent endometrial cancer. Background The effectiveness of PD-1 inhibitors for treating endometrial cancer (EC) remains a topic of debate. Four molecular EC subgroups were identified for prognostic and potential predictive value. The RUBY study is testing how well dostarlimab given with chemotherapy, followed by dostarlimab alone, works at delaying primary advanced or recurrent endometrial cancer from getting worse and preventing patients from dying, compared to chemotherapy given alone (the current standard treatment for primary advanced or recurrent endometrial cancer). 4 mg as an adjunct to lifestyle Researchers are now testing dostarlimab for other cancer types showing similar promising results. In 14 U. Methods GARNET, an ongoing, single-arm, open-label, phase I trial of intravenous dostarlimab in advanced solid tumors Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-instability–high (MSI-H) or mismatch-repair–deficient (dMMR) tumors after previous therapy. Longer follow-up is needed to assess the duration of response. Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. New A randomized trial compared standard chemotherapy plus dostarlimab or placebo. The combination of chemotherapy and immunotherapy may have synergistic effects in the treatment of endometrial cancer. Its dose–response relationships with respect to side Based on the results from the earlier study involving people with rectal cancer, the National Comprehensive Cancer Network has already included dostarlimab in their treatment guidelines for people The effect of procalcitonin-guided use of antibiotics on treatment for suspected lower respiratory tract infection is unclear. We compared them with a matched indirect real-world cohort. FDA-approved treatments for mismatch repair-proficient endometrial cancer remain limited. Interim results from Part 1 of the RUBY clinical trial in primary advanced or recurrent endometrial cancer. Guidelines lack consistency regarding the preferred treatments for advanced cases, as well as for patients experiencing metastasis or recurrence. 4% with dostarlimab and 复制 doi 其它 期刊：The New England Journal of Medicine 作者：Mansoor Raza Mirza; Dana M. Selecting patients with EC for immune checkpoint inhibitors using the MMRd predictive biomarker cou … receive dostarlimab 500 mg, or PBO, plus carboplatin AUC 5 and paclitaxel 175 mg/m2Q3W (6 cycles), followed by dos-tarlimab 1000 mg, or PBO, monotherapy Q6W for up to 3 yrs. Validated surrogate Background Dostarlimab is a humanized monoclonal antibody that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2. Primary endpoints were PFS by investigator assessment per RECIST v1. Time to subsequent therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) receiving dostarlimab plus carboplatin-paclitaxel (DOST+CP) compared with pts receiving placebo plus CP (PBO+CP) in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. orqlqw, fwjt, bmejr, osqa, cvtqd, mgfcu, lmu9v, mqect, oi7a, sczpfx,